Search

The objective: to identify pathognomonic symptoms and signs of different groups of pulmonary hypertension (PH), analyze the possibility of early diagnosis of patients with PH and the validity of the questionnaire.Material and methods. The questionnaire consists of 6 sections: clinical symptoms, physical examination, anamnestic information; diseases associated with PH; signs of pulmonary arterial hypertension (PAH) according to electrocardiography, chest radiography, echocardiography. All sections of the questionnaire were filled by physician. Was held an analysis of clinical symptoms, medical history, physical examination, methods of instrumental examination of 81 patients with idiopathic PH in comparison with 29 patients with PAH due to congenital heart defects - PAH-CHD, 36 patients chronic thromboembolic PH - CTEPH and the control group - 48 patients with essential hypertension. In addition, the validity of the questionnaire was evaluated: structural, the criterion and discriminant validity.Results. The leading complaint in IPAH patients was syncope; in patients with PAH-CHD the most often detected signs were cyanosis and accentuated pulmonary component of 2d heart sound; in patients with CTEPH - cough, they had a history of venous thrombosis of the lower limbs and the debut of the disease has been associated with pregnancy.Conclusion. Development and validation of a screening questionnaire allows to improve approaches to early detection of various forms of PH, allows identify specific symptoms that more typical of definite forms of PH.

Objective: development of a questionnaire for the early detection of pulmonary arterial hypertension (PAH), and its further introduction for a broad routine medical practice.Were identified clinical symptoms, allowing differentiate various forms of the disease (IPAH and PAH-CHD), because these forms of PAH most frequent in cardiology practice.Material and methods. The questionnaire includes 6 sections: clinical symptoms, physical examination, anamnestic information, diseases associated with pulmonary hypertension; signs of PAH according to electrocardiography, chest radiography, echocardiography. All sections of the questionnaire filled by physician. Was held a retrospective analysis of the clinical symptoms, physical examination, anamnestic information, methods of instrumental examination of 70 patients with IPAH in comparison with 29 patients with PAH-CHD and the control group - 48 patients with arterial hypertension (AH).Results. The leading complaints in patients with PAH are dyspnea (99%), palpitations (58%), fatigue (59%), syncope (21%), dry cough (28%), peripheral edema (38%). The physical signs of PAH include an accentuated pulmonary component of second heart sound (93%), cyanosis (40%). Most often, the development of pulmonary hypertension precipitated by stress, pregnancy, acute respiratory infections.Conclusion. According to the results we concluded that the developed questionnaire may be offered for wide use in routine clinical practice and recommended not only for screening patients with IPAH, but also with PAH-CHD.

Objective - to estimate the quality of life with therapy of trimetazidine in patients with idiopathic pulmonary hypertension, I-III functional class. Material and methods. In this study we included 29 patients (27 women and 2 men) aged 41.9±10 years. All patients had a common complain of angina-like symptoms. The patients were divided into 2 groups. The first group consisted of 11 patients (1 men and 10 women) who were additionally prescribed trimetazidine 35 mg twice daily for 24 weeks. The second group included 18 patients (1 men and 17 women) who continued to receive standard and specific therapy. At baseline and after 24 weeks all patients were examination, which included: laboratory (general and biochemical blood tests, D-dimer), clinical and instrumental examinations (electrocardiography, echocardiography, chest radiography, scintigraphy, a 6-min walking test, spirometry). We are take into consideration: age, sex, functional class (World Health Organization), complaints, tolerance, a 6-min walking test, Holter electrocardiogram in 12 lead, SF-36 questionnaire. Results. We analyzed the questionnaire SF-36 quality of life compared to before and after treatment trimetazidine: improvement in general health (p